Geron

Precision Medicine And Telomerase Inhibition Will Expand Therapeutic Markets

AnalystHighTarget

Not Invested

Community Contributor

Published

21 Aug 25

n/a

AnalystHighTarget's Fair Value

n/a

-69.4%

4.7%

-69.4%

4.7%

You can edit this narrative until Aug 21 9:27 PM. Then, changes will post as Updates.

Author's Valuation

US$681.3% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$6

81.3% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

36.55%

Biotech revenue growth rate

7.49%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.26%

Calculation

US$379.04m

Earnings '28

14.50x

PE Ratio '28

US$5.50b

Market Cap '28

US$5.50b

Market Cap '28

750.13m

No. shares '28

US$7.33

Share Price '28

US$7.33 Share Price '28

Discounted to 2025 @ 6.90% p.a.

US$6.00

Fair Value '25